Emerald Health Pharmaceuticals is collaborating with researchers and key opinion leaders at international centers of excellence to leverage multi-disciplinary expertise in cannabinoid science, drug delivery, formulation, and development. Our research collaborations provide EHP with the optimal platform on which to pursue the commercial development of new therapies for neurodegenerative, auto-immune, cardiovascular, metabolic and other diseases.
Emerald Biotechnology España
Emerald Biotechnology España (EBE), formerly known as VivaCell Biotechnology España, a scientific cannabinoid R&D company based in Córdoba, Spain, is a pioneer in the analysis of biological activities of cannabis phytoextracts for medicinal use and the proprietary variety of CBG-rich hemp (CARMA), The excellent track-record of EBE is backed by its origin, rooted in several European academic institutions, and supported over its 15 years of history by the most renowned scientists in cannabis research as founders and members of the Scientific Advisory Board of the company.
EHP acquired the IP from EBE for two series of molecules including, VCE-004.8, a CBD-derivative (the oral formulation of the drug candidate in clinical development is known as EHP-101), and VCE-003.2, a CBG derivative (the oral formulation of the drug candidate in preclinical development is known as EHP-102).
The science acquired by EHP was conducted over a 13-year period from 2004-2017 by two research scientists, Professor Eduardo Muñoz, MD, PhD (founder of EBE and Chief Scientific Officer of EHP) and Professor Giovanni Appendino, PhD (a member of EHP’s Scientific Advisory Board).
University Complutense (Madrid, Spain)
The Complutense University of Madrid is a public research university located in Madrid, and one of the oldest universities in the world. EHP-102 has been evaluated in preclinical models of Parkinson´s disease and amyotrophic lateral sclerosis (ALS) in collaboration with Prof. Javier Fernandez-Ruiz, a full Professor of Biochemistry and Molecular Biology at the University Complutense of Madrid (Spain). The results of these studies have been published in the Journal of Neuroinflammation (2018), Molecules (2019), Biochemical Pharmacology (2018) and Scientific Reports (2016).
The proneurogenic activity of EHP-102 on neuronal stem cells has been demonstrated in preclinical models of Huntington’s disease (HD) in collaboration with Dr. Ismael Galve-Roperh, an Associate Professor of Biochemistry and Molecular Biology at the University Complutense of Madrid (Spain). The results in the HD model have been published in Scientific Reports (2016) and Translational Neurodegeneration (2019)
Cajal Institute, Spanish National Research Council
The Cajal Institute (IC) is a research center in neurobiology, which belongs to the Spanish National Research Council(CSIC). EHP-101 has been evaluated in preclinical models of Multiple Sclerosis (MS), such as the experimental autoimmune encephalomyelitis (EAE) and the Theiler’s virus-induced encephalopathy (TMEV) murine models, in collaboration with Dr. Carmen Guaza, a full Professor at the Cajal Institute, Spanish National Research Council (Madrid, Spain). The data on the hypoxia mimetic activity of EHP-101 have been reported in the Journal of Neuroinflammation (2018).
University of Florida
The University of Florida is a top-ranked public research university located in Gainesville. Our lead cannabinoid derivatives are currently under evaluation in preclinical models of stroke, in collaboration with Dr. Eduardo Candelario-Jalil, an Associate Professor at the University of Florida.
Hospital Clínico de San Carlos
The San Carlos Clinical Hospital is located in the city of Madrid and administered by the Madrid Health Service , under the Ministry of Health of the Community of Madrid. Our lead cannabinoid derivatives are currently under evaluation in preclinical models of neonatal stroke, in collaboration with Dr. José A. Martinez-Orgado, Head of the Department of Neonatology, Hospital Clínico “San Carlos”.
Maimónides Institute for Biomedical Research (IMIBIC) – University of Córdoba
The Maimonides Biomedical Research Institute of Cordoba – IMIBIC, is a joint Institute of the University of Cordoba (UCO), the Reina Sofia University Hospital, and the Junta de Andalucía Regional government. IMIBIC brings together scientific research and medical practice to embrace integral projects with the ultimate aim to promote a much faster and efficient communication between clinical and preclinical research, and to generate knowledge of high impact with considerable potential of translation into practice, new therapies and innovative products.
VCE-004.8 has been evaluated in a preclinical model of metabolic syndrome induced by high fat diet in collaboration with Dr. Manuel Tena-Sempere, a full Professor of Physiology at the University of Córdoba (IMIBIC). The data on the anti-obesity activity of VCE-004.8 have been reported in the Scientific Reports (2018). In addition, a collaboration is ongoing with the proteomic unit and Prof. Eduardo Muñoz at the IMBIC to analyze plasmatic drug-related biomarkers.
Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche- Università del Piemonte Orientale
The Dipartimento di Scienze Chimiche, Alimentari, Farmaceutiche e Farmacologiche- Università del Piemonte Orientale is located in the city of Novara, Italy. To expand our library of compounds we are developing novel cannabinoid aminoquinone derivatives in collaboration with Dr. Giovanni Appendino, a full Professor of Organic Chemistry. Prof. Appendino was co-founder of Emerald Health Biotechnology España and also participated in the discovery of our lead candidates VCE-004.8 and VCE-003.2.